Health

Hemophilia B, a genetic bleeding disorder caused by a deficiency in factor IX, presents significant management challenges for those affected. Traditionally, individuals with hemophilia B rely on prophylactic factor IX replacement therapies administered intravenously. While these treatments have been a cornerstone of management, they do not offer a permanent solution, nor do they prevent the